(Health-NewsWire.Net, December 10, 2016 ) Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.
Report Highlights :
Publisher's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 16, 44, 36, 124, 25 and 2 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 24 and 8 molecules, respectively for Asthma. Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/asthma-pipeline-review-h2-2016
Report Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory). - The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001453559/sample
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
4D Pharma Plc AB Science SA AbbVie Inc Abeome Corporation Accolade Pharmaceuticals, LLC Acorda Therapeutics, Inc. Adamis Pharmaceuticals Corporation Advinus Therapeutics Ltd Afferent Pharmaceuticals, Inc. ALK-Abello A/S Allergopharma GmbH & Co. KG Almirall, S.A. Amakem NV Amgen Inc. AnaptysBio, Inc. AnGes MG, Inc. Antisense Therapeutics Limited ARA Healthcare Pvt. Ltd. Array BioPharma Inc. ASIT biotech s.a. Astellas Pharma Inc. AstraZeneca Plc Asubio Pharma Co., Ltd. Aurigene Discovery Technologies Limited Axikin Pharmaceuticals, Inc. Bioncotech Therapeutics SL Biotec Pharmacon ASA Boehringer Ingelheim GmbH CalciMedica, Inc. Cellceutix Corporation Cellular Biomedicine Group, Inc. Celon Pharma Sp. z o.o. Chiesi Farmaceutici SpA Circassia Pharmaceuticals Plc Cognosci, Inc. CSL Limited Cumberland Pharmaceuticals, Inc. Cynata Therapeutics Limited Daiichi Sankyo Company, Limited F. Hoffmann-La Roche Ltd. Foresee Pharmaceuticals, LLC Fountain Biopharma Inc. Genentech, Inc. GlaxoSmithKline Plc Griffin Discoveries BV Han Wha Pharma Co., Ltd. HitGen LTD Hydra Biosciences, Inc. iCeutica, Inc. iCo Therapeutics Inc. Immupharma Plc Infinity Pharmaceuticals, Inc. INOXIA Lifesciences GmbH Intech Biopharm Ltd Invion Limited Jiangsu Hansoh Pharmaceutical Co., Ltd. Johnson & Johnson Kissei Pharmaceutical Co., Ltd. Kolltan Pharmaceuticals, Inc. KPI Therapeutics, Inc. Kyowa Hakko Kirin Co., Ltd. Lead Discovery Center GmbH LegoChem Biosciences, Inc Ligand Pharmaceuticals, Inc. Lpath, Inc. Mabtech Limited Marinomed Biotechnologie GmbH MedImmune, LLC Merck & Co., Inc. Mitsubishi Tanabe Pharma Corporation Mycenax Biotech Inc. NAL Pharmaceuticals Ltd. NeoPharm Co., Ltd. Novartis AG Omeros Corporation Ono Pharmaceutical Co., Ltd. OPKO Health, Inc. Orbis Biosciences Inc Orion Oyj Oxagen Limited Palatin Technologies, Inc. Panacea Biotec Limited Panmira Pharmaceuticals, LLC. Paradigm Biopharmaceuticals Limited Peptinnovate Ltd Pfizer Inc. PharmaLundensis AB Pharmaxis Limited Pieris Pharmaceuticals Inc Pila Pharma AB Polyphor Ltd. Promedior, Inc. Prommune, Inc. Protectimmun GmbH Prous Institute for Biomedical Research S.A. Pulmagen Therapeutics LLP Pulmokine, Inc. Re-Pharm Limited Regeneron Pharmaceuticals Inc Respiratorius AB ReveraGen BioPharma, Inc. Rhizen Pharmaceuticals S.A. Saje Pharma, LLC Shire Plc Spring Bank Pharmaceuticals, Inc. Stallergenes Greer plc Sterna biologicals Gmbh & Co KG Sumitomo Dainippon Pharma Co., Ltd. Sun Pharma Advanced Research Company Ltd. Sunovion Pharmaceuticals Inc. Swecure AB Synermore Biologics Co Ltd Synovo GmbH Syntrix Biosystems, Inc. TaiwanJ Pharmaceuticals Co., Ltd. Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd. The International Biotechnology Center (IBC) Generium Therabron Therapeutics, Inc. Theravance Biopharma, Inc. Tolerys SA United BioPharma, Inc. Vectura Group Plc Verona Pharma Plc WhanIn Pharmaceutical Co., Ltd. Xencor, Inc. Yungjin Pharm. Co., Ltd. Zambon Company S.p.A.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001453559/discount
List of Figures: Number of Products under Development for Asthma, H2 2016 41 Number of Products under Development for Asthma - Comparative Analysis, H2 2016 42 Number of Products under Development by Companies, H2 2016 43 Number of Products under Investigation by Universities/Institutes, H2 2016 55 Comparative Analysis by Late Stage Development, H2 2016 57 Comparative Analysis by Clinical Stage Development, H2 2016 58 Comparative Analysis by Early Stage Products, H2 2016 59 Assessment by Monotherapy Products, H2 2016 208 Assessment by Combination Products, H2 2016 209 Number of Products by Top 10 Targets, H2 2016 210 Number of Products by Stage and Top 10 Targets, H2 2016 210 Number of Products by Top 10 Mechanism of Actions, H2 2016 222 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 222 Number of Products by Top 10 Routes of Administration, H2 2016 241 Number of Products by Stage and Top 10 Routes of Administration, H2 2016 241 Number of Products by Top 10 Molecule Types, H2 2016 243 Number of Products by Stage and Top 10 Molecule Types, H2 2016 243
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|